Category: ACN Newswire

東京, 2026年2月5日 - (亞太商訊 via SeaPRwire.com) - 專注於產業用貴金屬展開業務的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.（總公司：東京都中央區，執行總裁：田中 浩一朗）發表在接受委託製造包括體外診斷試劑在內之各種檢驗套組的業務中，確立可一次對應所有製程的綜合式的解決方案體制。迄今為止，TANAKA持續負責的主要是從開發和製造檢驗套組到批量製造萃取液，而此次設置分注及包裝萃取液的生產線，並整建了從開發到製成最終產品可一貫在公司內部完成的體制。藉此得以削減外包與運送所耗費的成本和時間，並可在更短期間內提供高品質產品。另外，預計於2026年3月新增導入最新型的自動組裝產線及萃取液分注設備，旨在進一步擴大生產能力和縮短前置時間。TANAKA綜合式的解決方案體制 透過強化一貫生產體制實現彈性應對透過確立此次綜合式的解決方案體制，從開發和製造檢驗套組到批量製造、分注、包裝萃取液的各個製程已可一貫接受委託。藉此，從客戶的開發階段到量產除了能夠持續支援之外，也可應對僅進行藥劑分注等個別製程的委託。透過在自家公司內部完成的生產製程，進而實現進一步強化穩定供應和品質管理。在廣泛疾病領域中檢驗套組的開發實績與推展實例推出了可應對廣泛傳染病的體外診斷試劑，像是包含流感病毒與新型冠狀病毒等在內的呼吸道傳染病，以及登革病毒與茲卡病毒等。這些檢驗套組已可應對像是唾液、血液及尿液等多種檢體，協助醫療現場進行迅速且準確的診斷。呼吸道傳染病病媒蚊傳染病婦產科・流感病毒・腺病毒・人類呼吸道融合病毒・人類間質肺炎病毒・新型冠狀病毒・A群β型溶血性鏈球菌（鏈球菌）・登革病毒・茲卡病毒・屈公病毒・驗孕試劑TANAKA檢驗目標疾病領域的推展實例技術基礎與今後展望TANAKA自約2006年起開始研究開發體外診斷試劑，並持續培育以金（Au）膠體粒子為核心的技術。擁有多項使用免疫層析法以支援試劑提高性能的技術，像是蛋白質固定化技術、非特異性吸附抑制技術，以及抗原抗體反應增強技術等。而在ISO 13485的認證下，亦運用這些技術接受委託製造高品質檢驗套組。今後將會運用這套綜合式的解決方案體制，也會在與合作夥伴企業進行協作的同時，致力於開發新的診斷試劑，為解決社會課題與推動醫療現場的進步作出貢獻。關於TANAKATANAKA自1885年（明治18年）創業以來，營業範圍以貴金屬為中心，並以此展開廣泛活動。在日本國內，以最高水準的貴金屬交易量為傲的TANAKA，長年以來除了進行產業用貴金屬產品的製造和販售外，並提供資產用與珠寶用的貴金屬商品。本集團以貴金屬專業團隊之姿，旗下的國內外各集團公司協調合作，使製造、販售與技術一體化，並供應相關產品與服務。2024 年度（2024年12月止）的合併營業額為8,469億日圓，擁有5,591名員工。產業事業全球網站https://tanaka-preciousmetals.com產品諮詢表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-on-industrial-products/新聞媒體諮詢處TANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/tw/inquiries-for-media/新聞稿: https://www.acnnewswire.com/docs/files/20260205_CT.pdf Disclaimer:ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE.NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

比利時莫爾塞爾, 2026年2月5日 - (亞太商訊 via SeaPRwire.com) - 亞格法醫療保健公司今日宣布，其於美國三大企業影像領域榮獲2026年度「最佳KLAS®」殊榮，其中兩項獎項更實現連續兩年蟬聯，彰顯該公司在提供以臨床醫師為核心的影像解決方案方面持續領先，其產品深受全球醫療機構信賴。此項殊榮正值KLAS研究成立三十週年之際，該機構三十年來始終透過獨立、數據驅動的洞察力，為醫療服務提供者發聲。愛格華醫療榮獲Best in KLAS獎項，彰顯其企業影像平台獲得客戶高度認可。該平台旨在賦能臨床醫師保持工作流暢度，簡化影像工作流程複雜性，並透過連通高效的影像與數據存取機制，助力臨床決策信心提升。最佳KLAS®評鑑 - 企業影像解決方案（美國）放射學企業影像解決方案：於PACS（小型系統 - 低於30萬份研究）領域以93.2%評分榮登榜首。XERO® Viewer：連續三年蟬聯通用影像閱片系統（影像類）榜首，評分達92.1%企業影像VNA系統：連續兩年榮登供應商中立檔案庫（VNA）類別榜首，評分達89.8%「在三大企業影像領域獲得認可——包括多次連續獲獎——有力印證了我們以臨床醫師為核心的戰略方針，」愛格華醫療總裁娜塔莉·麥考利表示。「醫療機構信賴我們能打造真正支援臨床醫師日常工作的影像環境，同時讓資訊技術與臨床領導者得以憑藉信心、效能及長遠視野開展工作。這項殊榮彰顯了我們合作夥伴關係的實力，以及我們始終如一地致力於透過互聯智能影像賦能醫療團隊。」針對本次獲獎，KLAS Research執行長亞當·蓋爾評論道：「最佳KLAS獎項得主在過去一年贏得了客戶的信任。這項認可將為未來數月醫療科技與服務領域的合作樹立卓越標竿。」KLAS Research全球影像副總裁莫妮克·拉斯班德補充道：「愛格華醫療在多個企業影像領域的卓越表現，反映出客戶的一致評價。醫療機構深知解決方案的價值——這些方案不僅能協助影像團隊提升當前工作效率，更為未來的成長與創新鋪設清晰路徑。」「最佳KLAS獎項」基於醫療服務提供者的直接反饋，表彰那些透過合作夥伴關係、卓越表現及對客戶需求的敏捷回應，持續展現卓越表現的供應商。AGFA HealthCare將於HIMSS 2026大會期間，攜手客戶與合作夥伴共同慶祝榮獲Best in KLAS殊榮，此舉彰顯該公司持續致力於推動大規模、互聯互通、智能且以人為本的影像解決方案。KLAS參考資料最佳KLAS獎項概覽：《2026最佳KLAS獎項：軟體與服務報告》企業影像分項報告：《2026最佳KLAS獎項：軟體與服務報告》關於亞格法醫療保健在亞格法醫療保健，我們深知要實現臨床效率與優質病患照護之間的關鍵平衡，首要之務在於提升臨床醫師的使用體驗。我們深知臨床醫師全神貫注於病例、傾注全力做出確信且明智診斷的重要性。正因如此，我們設計了企業影像平台以消除干擾因素。當干擾消弭，科技將成為思維的延伸，每位臨床醫師皆能掌握所需資源，發揮專業巔峰水準——這便是「流暢工作」的真諦。此信念貫穿我們所有行動——以使命、願景及客戶交付原則為指引，致力賦能臨床醫師並提升其體驗。亞格法醫療為亞格法集團旗下事業部。欲瞭解更多資訊，請造訪 www.agfahealthcare.com 並於 LinkedIn 追蹤我們。AGFA 及 Agfa 菱形標誌為 Agfa-Gevaert N.V. 比利時公司或其附屬機構之註冊商標。XERO 為 Agfa HealthCare N.V. 比利時公司或其附屬機構之註冊商標。本文所載所有資訊僅供參考之用，本刊所述產品與服務之特性可隨時變更，恕不另行通知。部分產品與服務可能未於您所在地區提供。請洽詢當地銷售代表以確認供應狀況。AGFA HealthCare 致力提供最精確資訊，惟對任何印刷錯誤概不負責。關於 KLAS ResearchKLAS Research 是領先的醫療保健資訊科技數據與洞察公司，致力透過放大醫療服務提供者的聲音來改善全球醫療服務。KLAS 將於 2026 年慶祝成立 30 週年，其透過基於直接客戶反饋的獨立研究評估供應商表現。Best in KLAS® 是 KLAS Research 的註冊商標。新聞聯絡人：Jessica Baldry，愛格法醫療保健全球行銷與傳播經理電話：+44 1206 413052電郵：jessica.baldry@agfa.com 消息來源：愛格法醫療保健 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 4, 2026) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") is pleased to report the additional analytical results of the Company's definition drilling campaign at the 100% owned flagship Trojárová Antimony-Gold Project (the "Project") in Slovakia as announced on November 4, 2025. The 2025 drilling campaign was designed to confirm historical drilling results and to support SLR Consulting's work towards establishing a current mineral resource estimate on the Project, which the company anticipates delivery of by the end of Q1, 2026, further discussed in the Company's January 9, 2025 announcement.These priority assay results represent the main mineralized zone from the third hole of the program, 25-TVA-003.Highlights of the Results from hole 25-TVA-003 Include:23.5 drilled (m) of 3.3 g/t Gold over a true width of 20.2m from 148.9m to 172.4mIncluding: 4.0m of 10.52 g/t Au over a true width of 3.4m from 157.9m to 161.9m1.9m of 2.53% Antimony over a true width of 1.6m from 169.9m to 171.8mScott Eldridge, Chief Executive Officer of the Company, commented, "We are thrilled with the second tranche of assays as we continue to see antimony grades that are consistent with historical results and higher than anticipated gold grades within the Trojárová Deposit. These strong gold results present the Company with new exploration opportunities that we are excited to evaluate. Trojárová represents the only antimony deposit in the European Union being advanced by modern mineral exploration and demonstrates characteristics that place it among the leading antimony projects globally. At a time when the need for secure, domestically sourced critical minerals is more pressing than ever, these results strengthen the project's potential importance to, and alignment with, the EU's objective of building a dependable, home-grown supply of essential raw materials."The Company additionally announces that logging and sampling of all drill core from the program is complete and all samples have successfully been delivered to ALS Laboratories in Roșia Montană, Romania for analysis. Additional results for all holes are pending.Table 1. Complete table of analytical results discussed in this release. Results exceeding 1.0 % Sb or 1.0 g/t Au are highlighted in red.Hole IDFrom (m)To (m)Drilledlength (m)True Width (m)Sample IDAntimony %Gold g/t25-TVA-003145.55146.50.950.813256260.016 0.01 146.5147.10.60.513256270.093 0.04 147.1148.110.863256280.123 0.52 148.1148.90.80.693256290.116 0.38 148.9149.910.863256311.145 1.1220.15m @ 3.3g/t True Width 149.9150.910.863256320.244 0.75 150.9151.910.863256330.057 0.7 151.9152.910.863256340.057 3.74 152.9153.910.863256360.279 4.5 153.9154.910.863256370.031 0.81 154.9155.910.863256380.189 1.05 155.9156.910.863256390.96 1.62 156.9157.910.863256410.807 1.3 157.9158.910.863256420.522 18.653.43m @ 10.52 g/tTrue Width158.9159.910.863256430.098 3.93159.9160.910.863256440.148 13.1160.9161.910.863256450.046 6.38161.9162.910.863256460.091 1.47 162.9163.910.863256470.169 0.76 163.9164.910.863256480.116 4.72 164.9165.910.863256490.088 1.76 165.9166.910.863256510.656 1.31 166.9167.910.863256520.307 1.37 167.9168.910.863256530.107 1.38 168.9169.910.863256540.247 1.19 169.9170.80.90.773256553.641.63m @ 2.53% True Width2.87 170.8171.810.863256561.542.66 171.8172.40.60.513256570.163 1.04 172.4173.410.863256580.136 0.08 173.4174.20.80.693256590.021 0.01 174.21750.80.693256610.582 0.35 17517610.863256621.57 0.71 17617710.863256630.097 2.01 177177.250.250.213256640.034 0.04 177.251780.750.643256660.507 0.34 17817910.863256670.103 0.24 17918010.863256680.261 0.62 18018110.863256690.1 0.54 181181.50.50.433256710.183 0.24 181.5182.510.863256720.018 0.01 182.5183.510.863256730.006 0.01 Figure 1. Gold mineralized drill core from hole 25-TVA-003 - 156.86m - 162.65m. Interval 157.9m to 161.9m yielded a composite grade of 10.52 g/t Au.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/282604_8fb84a54641daa6e_002full.jpgFigure 2. Map of 2025 and Soviet era diamond drillholes in the north-central portion of Military Metals Trojárová Project.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/282604_8fb84a54641daa6e_003full.jpgTable 2. Drillhole collar information for the Company's 2025 diamond drilling campaign at Trojárová. Locations presented are final and determined by a professional and qualified surveyor. WGS 84 / UTM Zone 33N DrillholeEastingNorthingElevation (m)Length (m)DipAzimuth25-TVA-0016626965358601640292.2-6522025-TVA-0026626855358668655289.7-7522025-TVA-0036625515358701634200.2-6522525-TVA-0046624755358809604256.5-5522525-TVA-0056623945358812580196-6023025-TVA-006662211535879556962.4-5722025-TVA-007662170535885255986.5-60210 Analytical and QA/QC ProceduresThe program was completed using PQ and HQ sized drill core. Sampled intervals were identified by logging geologists and assigned a unique sample identification number. Samples were split in two halves using a diamond bladed saw with one half remaining in the core box as a permanent record and the half placed in a plastic sample bag, both marked with a waterproof tag bearing the unique sample number which was also written on the sample bag in permanent marker. Samples were transported from the Company's secure facility by private courier to ALS Laboratories in Romania for geochemical analysis. ALS Laboratories is an independent ISO/IEC 17025:2017 and ISO 9001:2015 certified commercial laboratory with no relationship to the Company. The samples were analyzed using multi-element package ME_ICP41a and for gold using fire assay package Au-AA25. ME_ICP41a is an ore grade package involving digestion of a 0.4g sample by aqua regia with an Inductively coupled plasma - atomic emission spectrometry (ICP-AES) finish. The Au-AA25 fire assay method is an ore grade analysis using a 30g aliquot. The aliquot is mixed with flux composed of PbO and SiO2 with variable amounts of borax, soda ash and other reagents. The flux and sample are mixed, then heated at high temperature (>1,000°C) to decompose rock lattices and allow gold within the sample to be collected into a lead button. The button is placed in a porous cupel and heated again in an oxidizing environment to convert lead to lead oxide that is absorbed into the cupel, leaving the precious metals behind as a doré bead or prill. The gold content of the prill is then determined by atomic adsorption spectrometry.Both analyses are preceded by the preparation package Prep-31Y whereby the entire sample is crushed to 70% passing 2mm, a 250g split is collected by rotary splitter and pulverized to 85% passing 75 microns. Laboratory over-limits analysis methods were applied as required for both Sb and Au. A systematic QAQC protocol was employed that includes systematic insertion in the sample stream of certified reference materials and blank samples at a frequency of 1 in 10, plus analysis of duplicate pulp splits at a frequency of 1 in 30.About the Project and Historical ResourceDiscovered in the late 1970s, Trojárová was the focus of extensive surface and underground exploration over a 2km strike length from 1983 to 1995, with 63 core holes for a total of 14,330m, and 1.7km of underground workings completed. Efforts continued over the years as additional trenches were dug, and holes were drilled. Starting in 1990, underground development work began ultimately comprising a 300-meter-long adit connected to a 700-plus meter-long drive in the footwall of the mineralized zone with seven crosscuts into the mineralized zone for sampling purposes.These efforts culminated in a comprehensive study comprising drill logs, analyses, drill plans, maps and sections, deposit model studies, petrographic studies, metallurgical studies and more, now detailed in a multi-volume compendium of reports produced by the Slovak Geological Institute published in 1992, including a historical mineral resource estimate (see "Historical Resource Estimates" below). Per this historical estimate, at a cut-off grade of 1.0% antimony, Trojárová hosts 2.46 million tonnes averaging 2.47% antimony and 0.635 grams per tonne gold in a mineralized zone averaging 3.32 meters wide, containing approximately 60,000 tonnes of antimony in situ.Historical Resource EstimatesThe historical estimate related to the Trojárová Property was taken from a compendium produced by the Slovak Geological Survey, completed in March 1992 based on exploration work undertaking in the 1980s and 1990s. It is entitled (English translation): "FINAL JOB REPORT, PEZINOK-TROJAROVA, Geological Survey State Enterprise", report compendium number 78406 (Michel et al, 1992).The Slovak Geological Institute, the state agency that carried out all exploration and underground development work at Trojárová, classified the historical resources as "P1" and "C2" in the Slovak version of the Russian classification system, respectively. These are closest within the Canadian Institute of Mining, Metallurgy & Petroleum's ("CIM") classification system to "inferred mineral resources," which is defined by the CIM as that part of a mineral resource for which quantity and grade or quality are estimated on the basis of limited geological evidence gathered through appropriate sampling techniques from locations such as outcrops, trenches, pits, workings and drill holes.The historical work carried out appears comprehensive, detailed and at a professional standard. The Company considers this historical data to be relevant as the Company will use these data as a guide to plan future exploration programs. The Company also considers the data to be reliable for these purposes. A qualified person has not done sufficient work to classify the historical estimate as current, and the Company is not treating the historical estimate as current.Qualified PersonThe technical contents of this release were reviewed and approved by David Murray, P.Geo, VP-Exploration for Military Metals and a qualified person as defined by National Instrument 43-101.For more information about Military Metals Corp. and its critical minerals initiatives, please visit: https://www.militarymetalscorp.com.LinkedIn: https://www.linkedin.com/company/military-metals/X: https://x.com/militarymetalsFacebook: https://www.facebook.com/profile.php?id=61564717587797About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.com or info@militarymetalscorp.comFor enquiries, please call 604-537-7556Forward-Looking StatementsThis news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release includes the timing of the mineral resource estimate being currently conducted, and its completion at all, future drilling and exploration work at Trojárová, the continuation of the value of antimony, and the future needs of Europe and the E.U. specifically. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include geopolitical developments related to the supply and value of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the property that is the subject of this news release, the results of any future exploration activities, which cannot be guaranteed, and any other future activities in respect of the property held by the Target. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282604 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRUSSELS, BELGIUM, Feb 4, 2026 - (ACN Newswire via SeaPRwire.com) - Airwheel recently announced the continued rollout of its AI-driven rideable smart cabin suitcase solutions, marking a new phase in the evolution of intelligent travel mobility as global demand for smart transportation accelerates. Today, Airwheel’s sales and distribution network spans 68 countries and more than 4,600 retail locations worldwide. As its global expansion continues, the company’s electric and smart suitcases are transitioning from innovative products into high-frequency travel tools used by consumers around the world.Looking ahead, Airwheel will continue to advance the evolution of rideable smart luggage across technology, user experience, and application scenarios, allowing intelligent systems to integrate into travel in a more natural and intuitive way—so that travel becomes not just a means of transportation, but an opportunity to explore the world and enjoy life.As smart mobility continues to reshape global travel and transportation, intellectual property and design capability have emerged as key factors distinguishing true industry leaders from short-term innovators. In the field of rideable suitcase and smart mobility solutions, Airwheel has steadily strengthened its leadership position through long-term, systematic investment in technology and design.As one of the pioneers of the rideable smart luggage category, Airwheel has built a clear and robust competitive moat at the core technology level. To date, the company has accumulated more than 600 patents worldwide, covering critical areas such as motion control algorithms, electric drive systems, intelligent sensing, and structural design, including multiple international invention patents. In parallel, Airwheel has advanced its global intellectual property strategy, with trademarks registered in more than 168 countries and regions, providing a solid foundation for regulatory compliance, large-scale commercialization, and long-term brand development across international markets.Amid the rapid iteration of smart mobility products, design capability has become an equally important measure of product maturity. If patents represent technological depth and engineering strength, then international design awards serve as authoritative recognition of product philosophy, user experience, and comprehensive design excellence. In recent years, multiple Airwheel smart products have received recognition from leading global design awards, including the German iF Design Award, the U.S. IDEA Awards, the IAI Design Award, and the Berlin Design Award, demonstrating the brand’s consistent and high-level design output in the smart mobility space.These awards go far beyond aesthetics, evaluating products across dimensions such as usability logic, safety architecture, engineering integrity, human–machine interaction, and future application potential. Recognition from such professional juries indicates that Airwheel’s smart suitcase designs have been rigorously validated for both functional completeness and real-world usability, further enhancing the brand’s credibility in global markets.At the product level, the global popularity of the Airwheel SE3S Series marks a significant milestone in bringing rideable smart luggage into the mainstream. True product maturity is not defined solely by technical completeness, but by its ability to enter popular culture and everyday consumer awareness. Driven by social media and short-form video platforms, the Airwheel SE3S Series has become a favored electric suitcase among international celebrities, content creators, and fashion-forward travelers—often described as both a mobility tool and a “mobile lifestyle accessory.”Frequently seen in airports, fashion events, street photography, and travel scenarios, this rideable smart cabin suitcase not only serves a functional purpose but also delivers emotional value and personal expression. According to public data and platform analytics, content related to the Airwheel SE3S Series has generated tens of billions of impressions globally, transcending the boundaries of a single product category and becoming widely recognized as a fashionable travel symbol in the digital era.User feedback has further reinforced this dual identity. Many consumers describe the SE3S Series as “instantly recognizable” and “a travel companion that makes journeys lighter and more enjoyable,” strengthening its positioning at the intersection of smart mobility and lifestyle consumption.Notably, Airwheel has expanded its smart luggage ecosystem beyond adult users. The company also offers the SQ3 Series, a rideable smart suitcase designed specifically for children. By prioritizing safety and structural stability, the SQ3 Series introduces greater interaction and enjoyment into family travel, positioning smart luggage as an integral part of the parent-child travel experience.From a compliance perspective, the Airwheel SE3S Series is designed as a cabin suitcase, featuring a detachable lithium battery that meets airline safety standards, allowing it to be carried onboard flights in accordance with major international airline regulations. This design enables frequent, legal, and reliable use in airport environments worldwide, making it a practical choice for international travelers.Evolving from a mobility device into a source of emotional value and, ultimately, a widely recognized fashion travel product, the rise of the Airwheel SE3S Series signals that rideable smart luggage is becoming a natural part of everyday global travel.About AirwheelFounded in 2004, Airwheel is a global smart transportation device manufacturer with R&D, marketing, manufacturing, and logistics centers in the United States, Belgium, and China. The company has integrated the portable transportation industrial chain and built a globally recognized brand, serving more than 30 million users across 68 countries. Guided by its philosophy of “Free Intelligent Life,” Airwheel leverages technologies such as IoT sensors, robotics, and deep learning to develop intelligent mobility solutions that enhance freedom, joy, and everyday travel experiences worldwide.Media ContactCompany: AirwheelContact: Media TeamWebsite: https://www.airwheel.net Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ROMEOVILLE, IL, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications.This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup.With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgical instrument parts, medical device housings, components that see short-term body contact (< 30 days), and other non-implantable applications requiring strength, clarity, chemical resistance, and consistent processing.Key medical grade materials include:VESTAMID® Care ML PA12VESTAMID® Care ME PEBA elastomerTROGAMID® Care MX microcrystalline PA"Our healthcare customers rely on stable supply, world-class regulatory support, and materials that perform under demanding conditions," said Steve Harmon, Director, Key Accounts, Formerra. "Evonik's healthcare grades bring the combination of durability, processing consistency, and documentation support that medical manufacturers require. This expansion lets us strengthen the technical resources and materials pipeline available to teams developing next-generation devices.""Formerra's ability to serve the whole supply chain in the medical space, from design companies to compounders to medical device OEMs, with technical rigor and exceptional logistics and with already-proven successful demonstration in the industrial space, made this expansion with CARE brand Polyamide 12 products a natural step," said Basker Lalgudi, Business Manager, Global Medical Devices, Evonik. "Their healthcare expertise and focus help customers select and implement our materials with confidence across a range of critical applications."By adding Evonik's healthcare CARE brand materials, Formerra will offer customers a proven set of polyamide solutions that support regulatory pathways, design requirements, and long-term reliability. Formerra's team will provide material selection guidance, processing support, and regional supply chain readiness to help OEMs and molders accelerate development cycles.Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, Feb. 3-5, 2026.Key Details:Formerra will distribute Evonik's CARE brand healthcare grades across the U.S. and Canada.Materials include healthcare grades within the VESTAMID® L, VESTAMID® E, and TROGAMID® CX families, plus designated sustainable options.The agreement strengthens Formerra's medical portfolio and expands its support for fluid management, diagnostics, wearables, and device housings.Formerra will provide application guidance, regulatory documentation support, and supply chain continuity for medical customers.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways, driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About EvonikEvonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day. To learn more, visit www.evonik.com.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月4日 - (亞太商訊 via SeaPRwire.com) - 1月29日，由華泰保險經紀與上海國際再保險登記交易中心聯合承辦的菲律賓頭部能源集團Aboitiz Power全球統保項目中國市場保險排分風險路演會，在上海臨港國際再保險登記交易中心成功舉辦。作為Aboitiz Power 2026年度全球四地（上海、倫敦、新加坡、迪拜）路演的首站，是該集團首次登陸中國市場開展全球統保項目路演，也是上海國際再保險登記交易中心開業以來舉辦規模最大的國際保險業務路演，此次活動不僅彰顯了其對中國市場的高度認可，更印證了中國保險市場的承保實力、服務水平及華泰經紀的專業能力，為深化高水平對外開放、賦能全球能源合作注入強勁動力。上海自由貿易試驗區臨港新片區管理委員會金融貿易處處長殷軍，Aboitiz Power集團首席戰略官兼首席風險官史蒂夫‧邦茲，華泰保險經紀董事長杜奎峰，上海國際再保險登記交易中心總經理趙雷，以及20餘家保險公司、再保險公司的100餘位專家代表出席本次路演，共同探討為全球能源項目及綠色轉型提供風險保障的「中國方案」。鏈接全球，首啟中菲能源保險新征程作為Aboitiz Power全球統保路演的中國首秀，此次臨港活動搭建起中菲能源保險合作的橋樑，成為兩國深化能源領域協同、對接全球保險資源的重要起點。 上海自由貿易試驗區臨港新片區管理委員會金融貿易處處長殷軍表示，上海臨港正全力打造全球領先的國際再保交易市場，主動服務國家高水平對外開放戰略大局，並就支持產業發展的相關優惠政策進行全面解讀，同時還介紹了政策的具體落實情況。此次路演既是對中國保險市場、上海國際再保險登記交易中心及華泰經紀專業能力的認可和肯定，更是推動中國國際保險市場高質量發展、提升跨境金融服務能力的重要契機。Aboitiz Power集團首席企業服務官表示，中國與菲律賓有著諸多相似的發展境遇，本次交流將是阿博伊蒂斯能源與中國保險業界深化合作、攜手同行的起點。Aboitiz Power集團首席戰略官兼首席風險官史蒂夫‧邦茲介紹，作為菲律賓領先的能源企業，Aboitiz Power集團擁有百餘年的運營歷史，是菲律賓領先能源企業，發電量佔該國電力需求超20%，公司整體戰略佈局正積極深化與中國市場的全方位合作，是中國領軍能源建設和設備供應企業的重要合作夥伴。此次將整體保險業務向中國市場排分，包括由中國企業承建和設備供應的新能源建設項目，上海路演是集團全球佈局的重要一環。深耕佈局，共築全球能源風險保障網依託臨港新片區的制度優勢與行業資源，上海國際再保險登記交易中心、華泰經紀與各方力量協同發力，立足專業優勢深耕佈局，助力搭建全球能源項目風險保障體系，為能源合作築牢安全屏障。華泰經紀董事長杜奎峰表示，華泰經紀始終以服務共建「一帶一路」為使命，國際化與創新是公司「十五五」規劃的核心戰略。立足中國企業高質量「走出去」新階段，華泰經紀願與行業同仁攜手，通過產融深度融合，從服務中國出海企業與產品起步，延伸至賦能其全球上下游生態夥伴，助力中國實體產業提升海外綜合競爭力，構建互利共贏海外利益共同體。上海國際再保險登記交易中心總經理趙雷表示，中心將致力於打造高效標準、透明規範的新型再保險交易體系，推動我國保險業高質量發展、深化全球風險治理合作。當前，中國在國際保險市場佔有率仍有較大提升空間，鼓勵行業各方積極參與國際競爭與合作，把握這一推動中國保險市場實現新增長、開拓新格局的重要機遇。攜手共進，賦能「一帶一路」高質量發展此次路演凝聚行業共識、整合優質資源，推動各方在全球能源風險保障領域達成深度協作，為「一帶一路」能源合作注入保險力量，助力實現高質量發展。路演環節，Aboitiz Power與華泰經紀的專家先後介紹了項目排分情況、實施計劃及承保條件，中國太保、平安、人保、中再產險等機構圍繞項目風險保障、合作模式、跨境服務等核心問題開展深度交流，凝聚廣泛共識，為後續合作落地奠定堅實基礎。此前華泰經紀已成功協助Aboitiz Power在中國市場排分多個項目，此次路演旨在整合直保與再保資源，構建全球能源風險保障合力，探索「一帶一路」生態夥伴海外風險協同保障機制，打造可複製的風險管理範式。當前，「十五五」規劃開局起步，中國企業高質量「走出去」步伐持續加速，國家戰略的內涵與外延不斷豐富。未來，華泰經紀將持續以自身為核心，深耕國際化佈局，攜手行業同仁，以產融結合為紐帶，在構建「中資利益—中國元素—中國影響力」多層輻射圈的海外產業生態中，持續提升中國保險產業的國際話語權，推動跨境保險合作深化，為共建「一帶一路」高質量發展、促進中菲能源深度合作貢獻華泰力量。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 3, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa"), is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement (the "Offering"). The Company has closed on a total of 4,917,000 units (each, a "Unit") at a price of $0.125 per unit for gross proceeds of up to $614,625.00.Each Unit consists of one common share of the Company (a "Share") and one common share purchase warrant (each full warrant, a "Warrant"). Each of the 4,917,000 Warrants entitles the holder to acquire one additional share for a period of two years until February 04, 2028. The warrant exercise strike price is $0.15/share in the first three months and automatically converts to $0.20 per share then after for the remainder of the two years period.All issued Securities will be subject to a 4-month and one day hold-period, during which any resale or other transfer will be restricted in accordance with applicable securities laws.A Finder's Fees of $24,000 has been paid to registered financial institutions.Net proceeds from the offering will be used for general administration, exploration and development activities on the Company's projects in Arizona, and British Columbia, Canada. The Company will continue to raise the remaining placement in the coming week.The completion of the private placement remains subject to approval of the TSX Venture Exchange.None of the securities issued in the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act.About Casa Minerals Inc.The Company is engaged in the acquisition, exploration and development of mineral properties located in Canada and the USA. Casa owns ninety percent (90%) interest in the Congress gold mine (Arizona, USA). Additionally, the Company owns a one hundred percent (100%) interest in the polymetallic Pitman (BC, Canada) and has an option to acquire a seventy-five percent (75%) interest in the Arsenault VMS Property (BC, Canada).On Behalf of Board of Directors,Farshad Shirvani, M.Sc. GeologyPresident and CEOFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comhttps://www.casaminerals.comNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282620 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月3日 - (亞太商訊 via SeaPRwire.com) - 富衛集團有限公司（「富衛集團」或「富衛」）今天公佈消費者展望調查結果，顯示大多數亞洲中產階級對財務狀況感到焦慮，且對退休準備不足。隨着生活成本不斷上升及家庭責任增加，各世代的財務優先次序正被重新塑造。近四分三（71%）受訪的中產消費者對整體財務狀況感到壓力，三大主要憂慮包括：生活成本上升（71%）、高昂醫療費用（43%）以及擔心意外失業或收入減少（37%）。因此，他們的首要財務目標聚焦於兩至三年內的短期規劃。近半數（44%）受訪者旨在為家庭建立基本保障，而三分一（37%）則期望達致財務獨立。富衛集團分銷兼產品主張及策劃總監Lee Yen Ho表示：「顯然，亞洲各世代中產階層普遍存在財務脆弱感。隨著人口壽命延長與家庭結構演變，建立財務韌性以守護所愛，並將儲蓄轉化為可持續的終身收入，將變得日益重要。創造保險新體驗因而發揮關鍵作用。保險不僅能在困難時期提供保障，更有助建構抗風險能力、確保退休收入，讓所有人能自信地盡興人生。」調查亦揭示了明顯的跨代壓力：- X世代（出生於1965至1980年）面臨最艱難的平衡考驗：需同時負擔教育開支、償還房貸及準備退休。當中有62%擔心儲蓄無法抵禦通脹，52%將保障終身收入列為退休首要需求。- Y世代（出生於1981至1995年）同時肩負多重財務責任，其中49%擔心自己的退休儲蓄不足。大部分（85%）除養育子女外，還需供養父母。儘管近半數（47%）希望尋找單一高效的保險以保障多名家庭成員，但大多數（61%）從未聽聞相關的家庭保障計劃。- Z世代（出生於1996至2010年）財務壓力日增，53%預期未來五至十年會因日常開支上升而面對困難，另有46%認為保險產品價格過高。是次泛亞調查與市場研究公司益普索合作，訪問了逾9,000名年齡介乎於21至65歲的中產消費者，涵蓋富衛營運的十個市場：柬埔寨、香港特別行政區、印尼、日本、澳門特別行政區、馬來西亞、菲律賓、新加坡、泰國及越南。富衛在其市場提供多元產品，旨在加強保障、提升財務韌性及建立長期的財務安全。例如在香港推出「人仁保醫療保險計劃」提供靈活的家庭保障及設有免健康核保的添加自選保障。在日本，為了滿足日益增長的儲蓄和退休規劃需求，富衛推出了一款日圓整付保費年金產品，幫助個人和家庭建立穩定的退休收入來源。於泰國及新加坡推出的「FWD Sure Pension 」計劃及「FWD Invest Flexi Elite 」計劃協助客戶透過結構化收入及可持續的財富增長選項做好退休準備。於印尼，「FWD Critical First」保障計劃提供可負擔及對抗通脹的保障，協助家庭在生活成本上漲的環境下保障財務健康。關於富衛集團富衛集團（香港聯合交易所上市代號：1828）為泛亞洲人壽及健康保險公司，服務約3,400萬名客戶，業務遍及亞洲十個市場，包括印尼人民銀行人壽保險（BRI Life）。富衛秉持以客為先的方針及科技賦能的模式，致力為客戶帶來創新定位、簡單易明的產品和簡單的保險體驗。自2013年成立以來，富衛於部分全球發展最迅速的保險市場營運業務，專注為大眾創造保險新體驗。富衛集團在香港聯合交易所有限公司主板上市，股份代號為1828。如欲了解更多資訊，請瀏覽www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.comSource: FWD Group Holdings Limited Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

伊利諾州羅密歐維爾市, 2026年2月2日 - (亞太商訊 via SeaPRwire.com) - 高性能材料分銷領導企業福美拉今日宣布擴大分銷協議，將埃文斯CARE品牌醫療級產品納入其醫療產品組合。此涵蓋美國與加拿大的協議，為關鍵醫療應用領域的高性能聚醯胺材料開創全新通路。此擴展合作將於本週舉行的MD&M West 2026展會啟動，彰顯雙方以高性能材料、即時服務及穩定供應支持醫療市場的承諾。此舉亦延續兩家公司兩年的合作基礎——此前已將埃文斯VESTAMID®與TROGAMID®系列納入Formerra工程材料產品線。透過此次擴展，Formerra將支援艾維尼專為以下應用設計的醫療級產品：流體處理、藥物輸送、診斷系統、手術器械零件、醫療設備外殼、短期體內接觸部件（

香港, 2026年2月3日 - (亞太商訊 via SeaPRwire.com) - 全球最大釣魚裝備製造商樂欣戶外（股票代碼2720.HK）正式啟動招股，擬全球發售2820.5萬股，其中10%為香港公開發售。每股定價12.25港元。預計2月10日在聯交所掛牌上市。此次IPO擬集資約3.45億港元，中金公司擔任獨家保薦人。市場地位穩固，龍頭份額持續提升根據弗若斯特沙利文的權威數據，全球釣魚用具市場規模預計將於2029年達到1941億元，其中全球釣魚裝備市場展現出更快的增長勢頭，2025年至2029年的複合年增長率預計為9.5%，明顯高於行業整體。樂欣戶外作為全球最大的釣魚裝備製造商，市場份額為23.1%，同時在前五大廠商中佔據絕對主導地位。樂欣戶外亦是中國最大的釣魚裝備製造商，市場份額由2022年的23.4%穩步增長至2024年的28.4%，展現出持續增長潛力。中國釣魚裝備製造業也更為集中，按2024年收入計前五大釣魚裝備製造商所佔市場份額為39.4%。業績穩健增長，產品線覆蓋全面在財務數據層面，樂欣戶外營收保持高速穩健增長，2024年營收達5.73億元，較2023年實現23.8%的同比增長；2025年前八個月收入已達4.60億元，接近2024年全年的80%，顯示增長節奏穩健。公司2025年前八個月實現經營利潤7769.5萬元，接近2022年歷史較好水平，為公司戰略擴張提供了堅實的資本基礎。2025年前八個月淨利潤達5624.1萬元，淨利潤率維持在12.2%的健康水平，為公司戰略擴張提供了堅實的資本基礎。其中品牌業務增長迅猛，自有品牌Solar 2024年銷售額較2018年增長近三倍，儘管目前OBM業務佔比並不是很髙，但增長潛力巨大。同時，公司TO B業務持續發力，合作超過5年的客戶達84家，客戶黏性強勁，形成「TO B穩健托底+TO C突破增長」的雙增長格局，為長期資本回報提供穩定支撐。在產品矩陣層面，樂欣戶外為不同釣魚場景創造出了全面的產品解決方案。截至2025年8月31日的產品組合涵蓋10,000多個SKU，可適配釣魚人在不同地區及環境的需求，包括鯉魚釣、比賽釣、路亞釣、飛釣及冰釣等。市場前景廣闊，加碼品牌與未來 從全球格局來看，釣魚裝備市場正迎來結構性增長機遇。專業機構研究顯示，2025至2029年，全球釣魚裝備市場預計將以年均約9.5%的複合增速擴張，高於戶外行業整體水平，市場總規模有望邁向2000億元。我國垂釣裝備行業已邁入藍海發展階段，行業紅利為樂欣戶外的轉型提供了廣闊空間。機構數據顯示，2020-2024年，我國垂釣裝備行業市場規模年均複合增長率達18.92%，顯著高於全球同期水平，全球市場佔比持續提升，市場需求正從基礎功能滿足向專業化、場景化及個性化升級。此次IPO募資是樂欣戶外發展歷程中的重要里程碑，亦是其在資本層面提升核心競爭力、拓展戰略布局的關鍵舉措。伴隨全球休閒釣魚生活方式的熱潮，消費者對高品質釣魚裝備的需求持續攀升，新興市場的增速尤為顯著。作為全球規模最大的釣魚裝備製造商，樂欣戶外可依託自身產能與產品優勢，充分承接這一藍海市場的需求紅利，為品牌升級與市場拓展築牢基礎，迎來全新的發展機遇。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月3日 - (亞太商訊 via SeaPRwire.com) - 近日，由上海實業（集團）有限公司（以下簡稱“上實集團”）與Azzurra Capital聯合發起設立的亞洲環境科技合夥企業（Asia Environmental Technology Fund，簡稱“AETF”），已成功完成首關。AETF同步密集召開系列重要會議、深化多方合作對接，穩步推進落地運營與儲備項目佈局。作為上實集團與Azzurra Capital聯手打造的專業綠色投資平台，AETF擬定目標規模為5億美元。AETF將立足香港、面向全球，錨定綠色發展時代機遇，滙聚亞歐及中東優質資本支持，致力於成為跨境環境科技投資領域的標杆力量。依託「歐洲技術引進+亞洲企業出海」的雙向跨境賦能模式，AETF將國際私募股權的專業投研能力與上實集團深厚的產業資源深度融合，緊扣全球ESG主題尤其是環境科技投資目標，充分借助亞洲工業基礎與政策紅利，精選具備高增長潛力的投資標的。通過雙向賦能策略，既加速歐洲前沿環境技術在亞洲的場景落地，也助力亞洲綠色龍頭企業邁向全球，兼顧成熟項目的穩健回報與早期科技項目的成長潛力，助力亞洲穩步邁向「碳達峰、碳中和」綠色未來。AETF將重點涵蓋可再生能源產業鏈、能源轉化和儲能技術、賦能綠色低碳發展的數智化技術（AI、IoT及智能製造）、循環經濟與資源再生、可持續農業與未來食品體系、氣候科技（CCUS）及環境監測解決方案、具備全球出口競爭力的綠色消費品與可持續生活方式等領域。1月27日，AETF的GP公司召開首屆董事會，凝聚合作共識、明晰推進路徑、建立合規體系、儲備重點項目、細化落實舉措。在董事會召開期間，AETF董事和高管團隊圍繞落地運營、投資策略優化、多方合作拓展等召開了一系列專題會議，並同步拜訪了香港多家知名機構，圍繞環境健康領域潛在投資機遇、合作模式創新、跨境金融合規建設、項目協同聯動、優質資源分享等議題深入交流討論，為AETF精準對接香港本地優質資源、拓寬跨境合作版圖築牢根基。上實集團與Azzurra Capital將憑藉各自獨特優勢，構建起優勢互補、協同發展的良好合作格局。上實集團自1981年在香港成立以來，聚焦生命健康與環境健康兩大核心賽道，在產業整合、項目運營、本地資源對接等方面積累了深厚底蘊與豐富經驗。Azzurra Capital作為擁有成熟跨境基金管理經驗的知名投資機構，資產管理規模近9億美元，在歐洲、中東等地擁有廣泛的優質資源與優秀的投資業績，深耕綠色科技與可持續發展領域，專業能力獲行業認可。雙方攜手發起設立AETF，既是響應全球低碳轉型號召、踐行綠色發展理念的重要舉措，也是深化跨境投資合作、支援滬港協同發展，賦能亞洲環境科技產業高質量發展的具體實踐，更是雙方實現優勢互補、合作共贏的戰略抉擇。香港當前正在全力發展創科、綠色金融等新引擎，通過扮演更積極的「超級聯繫人」和「超級增值人」角色，在服務國家大局中實現自身的高質量發展。作為上實集團在港開展金融投資業務的平台，上實資本（香港）本次與Azzurra Capital合作攜手發起設立AETF，是上實資本（香港）緊抓當前香港發展機遇，服務在港發展，充分激發「香港所長」與「上海所能」的互補勢能，系統推動兩地創新鏈、產業鏈、資金鏈與人才鏈的深度融合的具體實踐，將為加快構建開放融合、連結全球的創新生態系統，為滬港國際科技創新中心建設提供支撐。上實集團首席金融投資官谷峰先生表示，此次與Azzurra Capital的合作，是上實集團將深厚產業資源與全球資本及頂尖投資管理經驗深度融合的重要戰略舉措。期待通過AETF這一平台，不僅投資技術，更致力於培育產業。我們將積極開放自身的應用場景與生態系統，為優秀的綠色科技企業提供從驗證到規模化發展的全方位支援，共同推動亞太區域的綠色轉型與高質量發展。Azzurra Capital創始合夥人Stefano Eugenio Marsaglia指出，亞洲作為全球低碳轉型的核心陣地，擁有巨大的投資潛力與廣闊的發展空間，綠色發展已成為不可逆轉的時代潮流。AETF的成功設立，搭建起了連接歐洲、中東與亞洲綠色投資市場的重要橋樑，未來將充分發揮雙方專業優勢，推動先進技術、優質資本與廣闊市場的跨境流動，全力打造亞洲環境科技投資領域的標杆，為全球低碳轉型貢獻力量。風勁潮湧正當時，揚帆奮進啟新程。AETF將以此次首關為重要契機，加速推進後續擴募進程，聚焦核心投資領域精準發力、推進優質項目落地見效，持續深化與各方機構的合作對接，積極開展品牌建設與行業交流。AETF將始終以「歐洲技術引進+亞洲企業出海」雙向策略為核心，持續作為雙方跨境綠色合作的核心載體，在各類行業峰會中傳遞合作價值、連結優質資源。AETF將以資本為紐帶、以創新為動力，賦能亞洲環境科技產業高質量發展，推動ESG投資理念深度落地，為全球低碳轉型注入持久動能、貢獻堅實力量。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MIAMI, FL, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Digi Power X Inc. ("Digipower X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, today announced that Hans Vestberg, former Chairman and Chief Executive Officer of Verizon Communications, has joined the Company as a senior advisor serving on its Advisory Board to support the Company's expansion strategy.Mr. Vestberg brings more than three decades of global leadership in mission-critical infrastructure, telecommunications networks, and large-scale capital deployment. He is widely recognized for leading Verizon's first commercial 5G deployment in 2018 and for advancing nationwide fiber, mobile edge computing, and next-generation network architectures.Prior to Verizon, Mr. Vestberg spent nearly three decades at Ericsson, including almost seven years as its Chief Executive Officer, where he helped build and operate global infrastructure facilitating approximately 35% of worldwide mobile traffic.Mr. Vestberg's appointment comes at a time when AI adoption is increasingly constrained, not by software or silicon, but by power availability, cooling capacity, and deployment speed. Digipower X is working on addressing this challenge through the deployment of the AI-Ready Modular Solution (ARMS) platform, designed to deliver Tier-3 modular AI data centers within approximately 180 days, supported by a vertically integrated power strategy and a growing portfolio of large-scale energy assets."Hans Vestberg built and scaled the physical infrastructure that helped enable the fiber, mobile, and 5G revolutions," said Michel Amar, Chairman and Chief Executive Officer of Digipower X. "He understands what most of the market overlooks: AI's bottleneck isn't algorithms or chips, it's power, cooling, and deployment speed. Hans knows how to execute infrastructure transformation at a national and global scale, and we expect his guidance will be invaluable as we expand our modular AI data center footprint.""I've spent over 30 years building the networks that move data," said Mr. Vestberg. "The next decade is about building the infrastructure that processes it. Digipower X is more than just a data center company. It controls its power, is developing the ability to deploy Tier-3 infrastructure in the near term, and is building a modular platform to address the exact constraints holding back large-scale AI deployment. Its focus on power availability and deployment speed first, real estate second, is exactly the right approach."Infrastructure Experience Aligned with AI ScaleDuring his tenure at Ericsson (2010-2016), Mr. Vestberg led more than 115,000 employees worldwide and positioned the company at the forefront of next-generation wireless technologies. At Verizon (2018-2025), he reshaped the organization around a network-first strategy, oversaw major investments in spectrum and fiber, and advanced distributed edge-compute capabilities to enable data-intensive and latency-sensitive applications.Mr. Vestberg insightfully noted at Davos 2024 that "one of the most important infrastructures of this century is digital infrastructure," and that AI workloads will increasingly migrate from centralized hyperscale facilities toward distributed locations supporting real-time inference and enterprise demand.Mr. Vestberg currently serves as a board member of BlackRock and Verizon.Addressing the Power and Deployment Constraint in AI InfrastructureDigipower X operates a combined-cycle power plant and three additional operating sites, with more than 200 megawatts of power currently online. The Company has secured development capacity to support AI infrastructure expansion over the next three years, with the ability to develop up to an additional 1.5 gigawatts of power capacity, including at major sites in North Carolina and West Virginia.In West Virginia, Digipower X has entered into a letter of intent relating to a 1.3-gigawatt power plant, which is being evaluated as a long-term site for AI data center and advanced computing infrastructure deployment."Hans recognizes that national AI competitiveness depends on solving power availability and deployment speed," said Gerard Rotonda, Board Member of Digipower X and former CFO of Deutsche Bank Wealth & Asset Management Americas. "His experience aligns directly with Digipower X's mission to deliver infrastructure at the scale and speed this market now requires."Vestberg's Strategic FocusIn his advisory role, Mr. Vestberg will work closely with Digipower X's executive team on:AI infrastructure deployment strategy and scaling frameworks;Distributed and edge-compute architectures for inference-driven workloads;Strategic partnerships with hyperscalers, enterprises, and infrastructure stakeholders;Power optimization and energy-efficient data center design;Tier-3 redundancy and mission-critical reliability standards; andInternational expansion strategy and site prioritization.About Digipower XDigipower X is an innovative energy infrastructure company that develops Tier III-certified modular AI data centers and drives the expansion of sustainable energy assets.For further information, please contact:Michel Amar, Chief Executive OfficerDigipower X Inc.www.digipowerx.comInvestor RelationsT: 888-474-9222Email: IR@digihostpower.comCautionary StatementTrading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking StatementsExcept for the statements of historical fact, this news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. Forward-looking information in this news release includes information about the Company's expectations concerning the potential contributions by our new advisor to the Company's strategic efforts, the potential further improvements to profitability and efficiency across the Company's operations, including, as a result of the Company's expansion efforts, potential for the Company's long-term growth and clean energy strategy, and the business goals and objectives of the Company. Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to: delivery of equipment and implementation of systems may not occur on the timelines anticipated by the Company or at all; future capital needs and uncertainty of additional financing; share dilution resulting from equity issuances; risks relating to the strategy of maintaining and increasing Bitcoin holdings and the impact of depreciating Bitcoin prices on working capital; statements regarding the timing, scale and expansion of AI and high-performance computing infrastructure; changes in demand for AI and high-performance computing; future data center capacity may not be realized at the level anticipated by the Company, or at all; development of additional facilities and installation of infrastructure to expand operations may not be completed on the timelines anticipated by the Company, or at all; ability to access additional power from the local power grid; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company's operations; the volatility of digital currency prices; and other related risks as more fully set out in the Annual Information Form of the Company and other documents disclosed under the Company's filings at www.sedarplus.ca and www.SEC.gov/EDGAR. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about, among other things, profitable use of the Company's assets going forward; the demand for data center capacity for AI and high-performance computing; and there will be no regulation or law that will prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company's normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainties therein. The Company undertakes no obligation to revise or update any forward-looking information other than as required by applicable law.SOURCE: Digi Power X Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEEDHAM, MA, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with the University of Minnesota to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.Under the agreement, research will be conducted at the University of Minnesota under the direction of Dr. Kevin Mayo, a recognized expert in biomolecular structure and nuclear magnetic resonance spectroscopy The collaboration is designed to further characterize carbohydrate-binding interactions that may play a role in future therapeutic and diagnostic applications.“This collaboration with the University of Minnesota represents an important step in strengthening the scientific foundation behind our carbohydrate-based technology platform,” said David Platt, CEO of Bioxytran. “By leveraging the University’s deep expertise in structural biology and advanced nuclear magnetic resonance spectroscopy, we aim to generate high-quality data that supports the continued evolution of our research and development pipeline.”Research FocusThe sponsored research program will explore how specific polysaccharides and related carbohydrate structures interact with target molecules relevant to biological systems. Using state-of-the-art nuclear magnetic resonance methodologies, the research team will analyze binding interactions, structural conformations, and affinity characteristics of select carbohydrate compounds. The work is expected to build on Bioxytran’s existing research into carbohydrate-based materials and their potential applications across biomedical and life-science domains. Findings from the study may help guide future development strategies and inform additional preclinical research initiatives.Academic–Industry CollaborationThe agreement reflects a shared commitment to advancing scientific knowledge through collaboration between academia and industry. The University of Minnesota will carry out the research in accordance with its established academic standards, ensuring scientific rigor, transparency, and adherence to institutional research policies.This type of partnership exemplifies how academic research institutions and innovative companies can work together to address complex scientific questions,” said Dr. Kevin Mayo, Principal Investigator and Professor at the University of Minnesota. “Our goal is to apply advanced analytical tools to generate insights that are both scientifically meaningful and relevant to real-world applications.”Timeline and StructureThe research term is expected to run through early 2027, with defined milestones, periodic progress reviews, and structured reporting. Bioxytran will provide funding to support research personnel, nuclear magnetic resonance facility access, and associated laboratory resources required to execute the program. In accordance with standard sponsored research practices, the University of Minnesota will retain ownership of any intellectual property generated through the research, while Bioxytran will receive broad rights to use the resulting research data for internal research and development purposes.Strategic SignificanceFor Bioxytran, the collaboration supports a broader strategy focused on strengthening its scientific validation, expanding academic partnerships, and advancing next-generation carbohydrate technologies. The company believes that well-characterized molecular interactions are a critical step toward unlocking new therapeutic pathways and accelerating innovation.The University of Minnesota continues to be recognized globally for its leadership in biomedical research and technology transfer, making it an ideal partner for companies seeking to bridge fundamental science and commercial development.About the University of MinnesotaThe University of Minnesota is one of the nation’s leading public research universities, known for its commitment to discovery, innovation, and the translation of research into real-world impact. Through industry partnerships and sponsored research programs, the University fosters collaboration that advances science and benefits society.About Bioxytran, Inc.Bioxytran is a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design, including programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation. Bioxytran’s common stock trades on the OTCQB under the symbol BIXT.Company Contact:Bioxytran, Inc.75 Second Avenue, Needham, MA 02494Phone: 617‑454‑1199Email: info@Bioxytraninc.comWeb: www.Bioxytraninc.comForward-Looking StatementsThis press release contains forward-looking statements, including statements regarding anticipated regulatory interactions, future clinical trials, trial designs, timing of data submission and publication, and potential therapeutic and commercial opportunities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are urged to review the Company’s risk factors disclosed in its reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10‑K for the year ended December 31, 2024. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年1月30日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司 （「康哲藥業」）欣然宣佈，旗下德鎂醫藥有限公司（「德鎂醫藥」，專業聚焦皮膚健康的創新型醫藥企業，正申請於香港聯合交易所有限公司主板獨立上市，詳見康哲藥業日期為2025年4月22日發佈的公告）已於2026年1月30日獲得中國國家藥品監督管理局（NMPA）批准磷酸蘆可替尼乳膏（白癜風適應症）（「產品」）新藥上市許可申請（NDA）。產品用於治療12歲及以上兒童和成人患者伴面部受累的非節段型白癜風，是中國批准的首款且唯一用於白癜風治療的靶向藥，滿足巨大未被滿足的臨床需求。磷酸蘆可替尼乳膏是經美國食品和藥物管理局（FDA）及歐洲藥品管理局（EMA）批准的首款也是唯一一款用於非節段型白癜風複色的藥物[1,2]，在產品正式獲得NDA批准之前，康哲藥業受益於國家賦予海南自由貿易港及樂城先行區（「樂城先行區」）「先行先試」政策、「港澳藥械通」政策、北京市及天津自貿試驗區的臨床急需進口藥品政策，已啟動磷酸蘆可替尼乳膏的試點應用。目前博鰲超級醫院已為超7,000名非節段型白癜風患者開具磷酸蘆可替尼乳膏處方，且廣州、深圳、東莞、佛山、中山、珠海、江門、惠州、北京及天津共二十餘家醫院已提供該藥品處方服務，體現了其臨床價值。產品在境外臨床研究與中國真實世界研究中均展現出積極結果：其在境外開展的兩項相同設計的III期雙盲、隨機、安慰劑對照研究（TRuE-V1和TRuE-V2）中，產品治療24周後達到主要療效指標面部白癜風面積評分指數改善至少75%（F-VASI 75）的患者比例均為29.9%，顯著高於安慰劑組的7.5%和12.9%，持續使用至52周，複色效果持續[3]。根據樂城先行區藥品真實世界數據應用試點項目有關規定，磷酸蘆可替尼乳膏在中國開展真實世界研究，療效積極，與境外關鍵臨床研究結果一致。境內外臨床研究中所有的次要療效指標均顯示出與主要療效指標一致的獲益趨勢，且白癜風治療效果隨療程延長持續改善。同時，根據樂城先行區安全性監測數據，未發現新的安全性事件，未發生導致停藥或退出的不良事件（AE），未發生研究藥物相關的嚴重不良事件（SAE）。 此次產品白癜風適應症獲批，將為國內千萬白癜風患者帶來治療新希望，滿足市場迫切的臨床需求。同時，產品將進一步豐富德鎂醫藥在皮膚治療領域的產品矩陣，並有望與現有處於商業化階段的創新藥益路取（替瑞奇珠單抗注射液）、獨家藥喜遼妥（多磺酸粘多糖乳膏），以及系列在研創新藥和皮膚學級護膚品等在專家網絡與市場資源等方面產生協同，提升德鎂醫藥在皮膚健康領域的地位。此外，康哲藥業於中國開展的磷酸蘆可替尼乳膏治療輕中度特應性皮炎患者的III期臨床試驗，已取得陽性結果。截至目前，康哲藥業正在中國積極推進磷酸蘆可替尼乳膏治療特應性皮炎的新藥上市申請，如若獲批上市，將為中國廣大特應性皮炎患者群體提供新的治療選擇。關於白癜風適應症白癜風是一種慢性自身免疫性疾病，其特徵是皮膚色素脫失，其發病原因為產生色素的細胞即黑素細胞的缺失。據估算，中國約有1030萬人患有白癜風，其中約820萬人患有非節段型白癜風[4]。現有療法，如外用糖皮質激素（TCS）及外用鈣調神經磷酸酶抑制劑（TCIs）存在臨床缺陷，長期用藥有不良反應或療效有限。磷酸蘆可替尼乳膏NDA獲批，成功填補了白癜風靶向藥物治療的空白，具有重大標誌性意義。關於磷酸蘆可替尼乳膏的更多資訊磷酸蘆可替尼乳膏（Opzelura®）是Incyte開發的選擇性JAK1/JAK2抑制劑蘆可替尼製成的一種創新型乳膏，在美國獲批用於局部治療成人及12歲及以上患者的非節段型白癜風，及2歲及以上非免疫力功能低下患者的輕度至中度特應性皮炎的局部短期和非連續性慢性治療。在歐洲，磷酸蘆可替尼乳膏被批准用於治療成年及12歲及以上青少年面部受累的非節段型白癜風。康哲藥業於2022年12月2日，通過德鎂醫藥的附屬公司與Incyte就磷酸蘆可替尼乳膏訂立合作和許可協議（「許可協議」），獲得在中國大陸、香港特別行政區、澳門特別行政區、台灣地區及東南亞十一國（「區域」）研發、注冊及商業化產品的獨家許可權利，以及在區域內生產產品的非獨家許可權利。德鎂醫藥的附屬公司已將磷酸蘆可替尼乳膏除中國大陸外的其他區域的相關權利再許可予康哲藥業（不包括德鎂醫藥及其附屬公司）。Incyte擁有磷酸蘆可替尼乳膏全球開發和商業化權利，在美國及歐洲以Opzelura®的名稱銷售。Opzelura®和Opzelura®標識是Incyte的註冊商標。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1.FDA批准資訊可在Incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2.EMA批准資訊可在Incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3.相關臨床研究資訊可在Opzelura®官網查詢，網址：https://www.opzelura.com/opzelura-prescribing-information4.數據來自灼識諮詢報告康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和-醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com